Nobuo Shimma

This inventor holds 35 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 7 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Chugai Seiyaku Kabushiki Kaisha, Hoffmann-La Roche Inc., Basilea Pharmaceutica Ag. Active years: 1989-2022.

USPTO Granted Patents = 35 (Patent Applications = 1)

% Patents Active = 57.1

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 1)

Average Co-Inventor Count = 6.5

ph-index = 9

Forward Citations = 419(Granted Patents)

Location History:

Kamakura, JP (2011 - 2013)
Chigasaki, JP (1989 - 2021)
Kanagawa, JP (1995 - 2022)

Company Filing History:

10 out of 984

Chugai Seiyaku Kabushiki Kaisha

patents

10 out of 5,016

Hoffmann-La Roche Inc.

patents

7 out of 72

Basilea Pharmaceutica Ag

Basilea Pharmaceutica Ag, a Swiss Company

The University of Tokyo

patents

8. 2 out of 834,350

Other

patents

where one patent can have more than one assignee

Years Active: 1989-2022

Loading Chart...

Areas of Expertise:

Ascochlorin Derivative

Nucleoside Derivatives

HCV Inhibitors

MEK Inhibitors

Pharmaceutical Chemistry

Cyclohexane Derivatives

Pyrimidine Derivatives

Hexacyclic Compounds

Pyrazolopyridine

N-benzylazolium Derivatives

Mitogen-Activated Protein Kinase

Azole Derivatives

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11298358 - Combination therapy using ascochlorin derivative (2022-04-12),

2. 10968186 - Ascochlorin derivative and use thereof as AMPK activator (2021-04-06),

3. 8648054 - 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication (2014-02-11),

4. 8609656 - Heteroarylphenylurea derivative (2013-12-17),

5. 8575391 - 5-substituted-2-phenylamino benzamides as MEK inhibitors (2013-11-05),

6. 8362236 - Macrocyclic compound (2013-01-29),

7. 8299252 - Pyrazolopyridine and pyrrolopyridine multikinase inhibitors (2012-10-30),

8. 8084645 - 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors (2011-12-27),

9. 8071567 - 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication (2011-12-06),

10. 8048897 - Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes (2011-11-01),

11. 8022205 - Pyrimidine derivatives as PI3K inhibitor and use thereof (2011-09-20),

12. 7915232 - 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication (2011-03-29),

13. 7745663 - 5-Substituted-2-phenylamino benzamides as MEK inhibitors (2010-06-29),

14. 7608601 - 4'-Substituted nucleoside derivatives as inhibitors of HCV RNA replication (2009-10-27),

15. 7459561 - N-substituted carbamoyloxyalkyl-azolium derivatives (2008-12-02),

Title: Innovator Spotlight: Nobuo Shimma

Introduction: Nobuo Shimma, a prolific inventor based in Chigasaki, Japan, holds an impressive portfolio of 35 patents. His groundbreaking work primarily focuses on medical applications, particularly concerning the regulation and treatment of diseases linked to adenosine monophosphate-activated protein kinase (AMPK) dysregulation.

Latest Patents: Among his latest innovations are two notable patents. The first is a combination therapy utilizing an ascochlorin derivative designed to treat or prevent conditions involving AMPK dysregulation, especially various forms of cancer. This invention incorporates a unique compound presented by a specific formula along with an immune checkpoint inhibitor, promising a potent therapeutic approach. The second patent presents a novel ascochlorin derivative that acts as an AMPK activator, intended for treating or preventing diseases linked to AMPK dysregulation. This patent details a compound formulated for pharmaceutical applications, contributing further to the therapeutic landscape.

Career Highlights: Nobuo Shimma has significantly impacted the pharmaceutical field, collaborating with prestigious companies such as Chugai Pharmaceutical Co., Ltd. and Hoffmann-La Roche Inc. His career reflects a commitment to innovation and the advancement of medical treatments, underscoring the importance of intellectual property in enabling research and development.

Collaborations: Throughout his career, Shimma has worked alongside notable colleagues, including Isao Umeda and Takuo Tsukuda. Their collaborative efforts have fostered an environment of creativity and scientific exchange, driving forward important research initiatives.

Conclusion: Nobuo Shimma stands out as a vital contributor to the field of biotechnology and pharmaceuticals with his innovative approaches to addressing AMPK-related diseases. His patented inventions not only highlight the importance of intellectual property in fostering innovation but also exemplify the potential for research to translate into impactful medical treatments. The work of inventors like Shimma is crucial for advancing health solutions and improving patient outcomes globally.